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The present study was initiated with the objective of studying the in vitro dissolution behavior of gliclazide 
from its solid dispersion with polyethylene glycol 6000. In this work, a solid dispersion of gliclazide 
with polyethylene glycol was prepared by the fusion method. In vitro dissolution study of gliclazide, its 
physical mixture and solid dispersion were carried out to demonstrate the effect of PEG 6000. Analytical 
techniques of FT-IR spectroscopy, differential scanning calorimetry and X-ray diffractometry were used 
to characterize the drug in the physical mixtures and solid dispersions. The dissolution studies of solid 
dispersion and physical mixture showed greater improvement compared to that of the pure drug. The 
mechanisms for increased dissolution rate may include reduction of crystallite size, a solubilization 
effect of the carrier, absence of aggregation of drug crystallites, improved wettability and dispersbility 
of the drug from the dispersion, dissolution of the drug in the hydrophilic carrier or conversion of drug 
to an amorphous state. The FT-IR spectra suggested that there was no interaction between gliclazide 
and PEG 6000 when prepared as a solid dispersion. DSC and XRD study indicated that the drug was 
converted in the amorphous form.
Uniterms: Gliclazide. Polyethylene glycol 6000. Solid dispersion. In vitro dissolution.
O presente trabalho foi realizado com o objetivo de estudar o comportamento in vitro da dissolução da 
gliclazida a partir da sua dispersão sólida com polietileno glicol 6000. Neste trabalho, as dispersões sólidas 
de gliclazida com polietileno glicol foram preparadas pelo método de fusão. Os estudo de dissolução 
in vitro da gliclazida, na mistura física e nas dispersões sólidas foram realizados para demonstrar o efeito 
de PEG 6000. Técnicas analíticas como espectroscopia FT-IR, calorimetria diferencial de varredura e 
difração de raios-X foram empregadas para caracterizar o fármaco nas misturas físicas e nas dispersoes 
sólidas. Os estudos de dissolução demonstraram maior melhoria. Os mecanismos para aumentar a 
velocidade de dissolução podem incluir a redução do tamanho dos cristais, a solubilização do carreador, 
a ausência de agregação dos cristais do fármaco, a melhoria da molhabilidade e dispersibilidade do 
fármaco a partir da dispersão, a dissolução do fármaco no carreador hidrofílico ou conversão da forma 
cristalina do fármaco para estado amorfo. Os espectros de FT-IR sugeriram que não houve interação 
entre gliclazide PEG 6000 e na sua combinação. Os estudos de DSC e DRX indicaram que o fármaco 
foi convertido para a forma amorfa.
Unitermos: Gliclazide. Polietileno glicol 6000. Sólidos/dispersão. Dissolução in vitro.
INTRODUCTION
Solid dosage forms such as tablets and capsules repre-
sent the highest share in the market despite advancements 
in innovative dosage forms. Drug dissolution from oral 
solid dosage forms depend on the release of the drug from 
the dosage form and subsequent solubilization of drug par-
ticles in physiological fluid. The dissolution characteristics 
of poorly water-soluble drugs remain a major problem for 
the pharmaceutical industry because dissolution is the rate-
limiting process in the absorption of these drugs from solid 
dosage forms. Among the various approaches employed 
to improve the dissolution of poorly soluble drugs, solid 
dispersion has been proven successful. Fast or immediate 
drug dissolution from solid dispersions has been observed 
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due to increased wettability, improved dispersibility of drug 
particles, existence of the drug in amorphous form with 
improved solubility, and absence of aggregation of drug 
particles (Chowdary et al., 1995; Kerc et al., 1998).
Solid dispersion is one of the most widely-used 
techniques for dissolution improvement (Chiou, Riegel-
man, 1971). Two basic procedures used to prepare solid 
dispersions are the melting or fusion (Sekiguchi, Obi, 
1961) and solvent evaporation techniques (Tachibana, 
Nakamura, 1965).
The mechanisms for increased dissolution rate may 
include reduction of crystallite size, a solubilization effect 
of the carrier, absence of aggregation of drug crystallites, 
improved wettability and dispersibility of a drug from 
the dispersion, dissolution of the drug in the hydrophilic 
carrier or conversion of the drug to an amorphous state 
(Ford, Robenstein, 1986; Craig, 2002; Liu et al., 2005; 
Shah et al., 2007).
Gliclazide, 1-(3-azabicyclo (3,3,0)oct-3yl)-3-p-tolyl-
sulphonylurea is a potential oral hypoglycemic drug which 
is useful for the treatment of non-insulin-dependent diabetes 
mellitus (Palmer, Brogden, 1993; Mailhot, 1993). Due to 
short duration of action, it is considered suitable for diabetic 
patients with renal impairment and for elderly patients that 
have reduced renal function and are in use of sulphonylurea 
treatment, which may increase the risk of hypoglycemia 
(Tessier et al., 1994). However, gliclazide has low solubi-
lity and low dissolution in gastric fluids and hence shows 
variation in bioavailability (Gillman et al., 1990).
MATERIAL AND METHODS
Materials
Gliclazide was obtained from Indi Pharma Pvt. Ltd., 
Goa (India). Polyethylene glycol 6000 was purchased from 
Qualigens Fine Chemicals (India). Sodium hydroxide 
and potassium dihydrogen phosphate were purchased 
from Loba Chemie, Mumbai, and hydrochloric acid from 
Ranbaxy Fine Chemicals Ltd., New Delhi.
Methods
Physical mixtures and corresponding solid dispersion
Physical mixtures of gliclazide with three different 
mass ratios (1:1, 1:3 and 1:5 as PM 611, PM 613 and PM 
615) of PEG 6000 were prepared in a glass mortar by light 
trituration for 5 minutes. Solid dispersions were prepared 
by the fusion method (Sekiguchi, Obi 1961). Polyethylene 
glycol 6000 was placed in a porcelain dish and allowed 
to melt by heating up to 70 °C. To the molten mass, an 
appropriate amount of gliclazide was added, and the mix-
ture stirred constantly until a homogenous dispersion was 
obtained. For rapid solidification, the resultant solution 
was cooled in an ice bath and stored in dessicator for 24 h. 
The solid was then scraped, pulverized and passed through 
a sieve. The prepared solid dispersions at different mass 
ratios (1:1, 1:3 and 1:5 as SD 611, SD 613 and SD 615) 
were then introduced into glass bottles, sealed and stored 
in a dessicator until further use.
In vitro dissolution study
Dissolution of drug powder, gliclazide (40 mg), its 
physical mixtures (in drug: PEG 6000 ratio 1:1, 1:3 and 
1:5 as PM 611, PM 613 and PM 615) and solid dispersions 
(in drug: PEG 6000 ratio 1:1, 1:3 and 1:5 as SD 611, SD 
613 and SD 615) with PEG 6000 (equivalent to 40 mg), 
was carried out using USP dissolution test apparatus (Type 
II) at a temperature of 37 ± 0.5 °C, at 100 rpm using 900 
mL of dissolution medium. The dissolution study was 
carried out separately for two hours in 2 different dis-
solution mediums viz. hydrochloric acid buffer (pH 1.2, 
0.2 M potassium chloride (50 mL) and 0.2 M hydrochloric 
acid (85 mL) and phosphate buffer (pH 7.4) (USP, 2000). 
Samples (5 mL) were withdrawn at predetermined time 
intervals (5, 10, 15, 30, 45, 60, 90 and 120 minutes), filte-
red through Whatman filter paper No. 41, suitably diluted 
and assayed for gliclazide at 226 nm. Sink conditions 
were maintained by replenishing the medium with equal 
amounts (5 mL) of dissolution medium. The percentage 
of gliclazide dissolved was calculated from the regression 
equation generated from standard data.
Characterization of gliclazide and its solid dispersions 
(Leuner, Dressman, 2000)
· FT-IR study
The samples, gliclazide, PEG 6000, their physical 
mixtures and solid dispersions were previously ground and 
mixed thoroughly with potassium bromide. Forty scans 
of each sample were obtained at a resolution of 4 cm–1 
from 4500 to 400 cm–1 using a FT-IR spectrophotometer 
(8101A, Shimadzu Co., Japan).
· DSC
The DSC measurements were performed on a di-
fferential scanning calorimeter (DSC-60, Shimadzu Co., 
Japan) with a thermal analyzer. Accurately weighed sam-
ples (about 5–10 mg) were heated in hermetically sealed 
aluminum pans under a nitrogen atmosphere at a flow rate 
of 20 mL min–1 with a scanning rate of 15 °C min–1 from 60 
to 250 °C. An empty aluminum pan was used as a reference.
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· X-ray diffractometry
The state of gliclazide, its physical mixtures and 
solid dispersions was evaluated with X-ray powder diffrac-
tion. Diffraction patterns were obtained using an XPERT-
PRO diffractometer (PANalytical Ltd., The Netherlands) 
with a radius of 240 mm. The Cu Kα radiation (Kα 1.54060 
Å) was Ni filtered. A system of diverging and receiving 
slits of 1° and 0.1 mm, respectively, was used. The pattern 
was collected with 40 kV of tube voltage and 30 mA of 
tube current and scanned over the 2θ range of 5–60°.
RESULTS AND DISCUSSION
In vitro dissolution study
Physical mixtures of drug with PEG 6000 at three 
different mass ratios showed 65.90%, 43.13% and 
65.14% drug release, while solid dispersions showed 
48.01%, 63.98% and 56.27% during the first hour of 
study. The percentage drug release from solid dispersions 
was initially slow but at the end of 120 min was 90.43%, 
92.97% and 97.93%. This may be due to the formation 
of a drug-rich surface layer which further prevents ero-
sion of the matrix or could be due to rapid dissolution 
of carrier.
Similar dissolution studies were carried out in 
phosphate buffer. In the first 30 min, cumulative % drug 
release from physical mixtures was 57.40%, 62.26% 
and 67.10, respectively, while solid dispersions showed 
52.94%, 62.62% and 57.40%. At the end of the study, 
solid dispersions showed 92.40%, 94.89% and 98.00 
% drug release and physical mixtures showed 84.02%, 
86.37% and 89.22% drug release. The dissolution test 
was repeated in triplicate. Drug dissolved at specific time 
periods was plotted on cumulative percent release versus 
time (hours) curves.
FIGURE 1 - % drug release in hydrochloric acid buffer (pH 1.2). PM 611, PM 613 and PM 615 indicates physical mixtures of 
drug: PEG 6000 at 1:1, 1:3 and 1:5 ratios. SD 611, SD 613 and SD 615 indicate solid dispersions of drug: PEG 6000 at 1:1, 1:3 
and 1:5 ratios.
FIGURE 2 - % drug release in phosphate buffer (pH 7.4). PM 611, PM 613 and PM 615 indicates physical mixtures of drug: PEG 
6000 at 1:1, 1:3 and 1:5 ratios. SD 611, SD 613 and SD 615 indicate solid dispersions of drug: PEG 6000 at 1:1, 1:3 and 1:5 ratios.
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The results indicated that, as the concentration 
of polymer in the dispersed system increases, dissolu-
tion of poorly soluble drug also increases. In all cases, 
solid dispersions exhibited faster and almost complete 
dissolution compared to the pure drug and its corres-
ponding physical mixtures. The possible mechanisms 
responsible for increased dissolution could be reduction 
of crystallite size, a solubilization effect of the carrier, 
absence of aggregation of drug crystallites, improved 
wettability and dispersibility of a drug from the disper-
sion, dissolution of the drug in the hydrophilic carrier, 
and conversion of the drug to an amorphous state (De-
sai, Liu, 2005; Ozkan, 2000).
FT-IR study
The FT-IR spectrum of Gliclazide showed a sharp 
concave curve at 1709 cm-1 for the carbonyl group. For the 
sulphonyl group bands, the spectrum showed stretching 
peak at 1164 cm-1 and 1350 cm-1 and a peak at 3272 cm-1 
evidenced the amino group. The spectrum of PEG 6000 
showed important peaks at 3425 cm-1 (O-H stretch), at 
1109 cm-1 (C-O-C stretch) and at 2889 cm-1 (C-H stretch). 
Consequently, the FT-IR spectra of both solid dispersion 
and physical mixture seemed to be only the summation of 
Gliclazide and PEG 6000 spectra. These results suggested 
that there was no interaction between Gliclazide and PEG 
6000. The results are given in Figure 3.
DSC
Gliclazide showed an endothermic reaction and its 
melting peak was at 172.3 °C. The thermal behavior of 
PEG 6000 exhibited a sharp endothermic peak at 62.2 °C. 
A slight difference was evident in the thermograms of the 
physical mixture and solid dispersion, showing a single 
sharp melting peak at 60.2 °C and 60.5 °C, respectively. 
The complete disappearance of Gliclazide melting peak 
observed in both PM and SD was attributable to the 
complete miscibility of the drug in the melted carrier. 
The enthalpy of melting of drug in solid dispersion (ΔHf: 
-151.5J/g) was gradually decreased compared to the drug 
(ΔHf: -126.9 J/g). This phenomenon could be attributed 
to the amorphous form of the drug in solid dispersion. The 
results are given in Figure 4.
X-ray diffractometry study
Numerous diffraction peaks of gliclazide observed 
at 2θ of 10.5, 15.0, 16.7, 17.0, 17.8, 18.1, 18.4, 20.8, 21.1, 
22.0, and 26.2 indicated the presence of crystallinity. Pure 
PEG 6000 showed two peaks with highest intensity at 
FIGURE 3 - FT-IR spectrum of Gliclazide, PEG 6000, their physical mixture and solid dispersion.
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2θ of 19.3 and 23.4, along with other peaks at 2θ of 13.7 
and 27.4. The physical mixture showed peaks of PEG 
6000 along with low intensity peaks of Gliclazide. The 
diffraction pattern of the solid dispersion showed peaks of 
Gliclazide of lower intensity. Some peaks shown by pure 
Gliclazide were also found to be absent, and the intensity 
of peaks observed was markedly reduced in the XRD 
spectrum of the solid dispersion. The results indicated that 
the drug in solid dispersion was present in an amorphous 
state. Results are given in Figure 5.
CONCLUSION
The approach of the present work was to characteri-
ze the solid dispersion of a Class II drug (Biopharmaceutic 
Classification System) and study its effect on dissolution. 
Infra-red spectroscopy studies indicated no interaction 
between drug and carrier. The drug was completely mis-
cible in water-soluble carrier. The enthalpy of melting 
of the drug in solid dispersion was gradually decreased 
compared to pure drug, as revealed by DSC thermograms. 
The XRD study showed that the drug was present in amor-
phous form. The study showed increased dissolution rate 
FIGURE 4 - DSC scans of Gliclazide, PEG 6000, their physical 
mixture and solid dispersion
FIGURE 5 - XRD pattern of Gliclazide, PEG 6000, their physical 
mixture and solid dispersion
with the formation of solid dispersion. Solid dispersion 
performed better than the corresponding physical mixture 
while physical mixture performed better than the pure 
drug. The mechanisms responsible for this improvement 
could be a solubilization effect of the carrier, miscibility 
of the drug in melted carrier, and conversion of the drug 
from crystalline to amorphous form.
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